{"id":23422,"date":"2022-12-22T18:03:00","date_gmt":"2022-12-22T10:03:00","guid":{"rendered":"https:\/\/flcube.com\/?p=23422"},"modified":"2025-01-27T18:08:22","modified_gmt":"2025-01-27T10:08:22","slug":"shaanxi-panlong-receives-patents-for-coronavirus-3cl-protease-inhibitor","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=23422","title":{"rendered":"Shaanxi Panlong Receives Patents for Coronavirus 3CL Protease Inhibitor"},"content":{"rendered":"\n

China-based Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864<\/a>) has announced receiving two patents (US11518759B1, US11530195B1) in relation to a development project titled “Coronavirus 3CL Protease Inhibitor Development,” in collaboration with Shaanxi University of Science and Technology. The patents cover “PROTACs [proteolysis-targeting chimeric molecules] based on VHL ligand targeting coronavirus 3CL protease, preparation method and application thereof.”<\/p>\n\n\n\n

Patent Details and Innovation<\/strong>
The two patents are based on PROTACs designed and synthesized based on PLC01, the company’s novel coronavirus 3CL protease inhibitor drug candidate. Cell and animal experiments have shown that the PROTACs developed have excellent 3CL protease degradation ability. This marks the first time that anti-coronavirus PROTACs have received patent protection worldwide, highlighting Shaanxi Panlong’s leadership in innovative drug development.<\/p>\n\n\n\n

Future Prospects and Strategic Implications<\/strong>
The receipt of these patents positions Shaanxi Panlong to further advance its research and development efforts in the field of coronavirus treatments. By leveraging the innovative PROTAC technology, the company aims to address significant unmet medical needs and contribute to the global fight against coronavirus infections. This strategic move underscores Shaanxi Panlong’s commitment to innovation and improving patient outcomes through advanced therapeutic solutions.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864) has announced receiving two patents (US11518759B1,…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[13,1644,73,1643,70],"class_list":["post-23422","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-covid-19","tag-panlong-pharmaceutical","tag-patents","tag-she-002864","tag-tpd"],"yoast_head":"\nShaanxi Panlong Receives Patents for Coronavirus 3CL Protease Inhibitor - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864) has announced receiving two patents (US11518759B1, US11530195B1) in relation to a development project titled "Coronavirus 3CL Protease Inhibitor Development," in collaboration with Shaanxi University of Science and Technology. The patents cover "PROTACs [proteolysis-targeting chimeric molecules] based on VHL ligand targeting coronavirus 3CL protease, preparation method and application thereof."\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=23422\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shaanxi Panlong Receives Patents for Coronavirus 3CL Protease Inhibitor\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=23422\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-22T10:03:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-27T10:08:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23422#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23422\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shaanxi Panlong Receives Patents for Coronavirus 3CL Protease Inhibitor\",\"datePublished\":\"2022-12-22T10:03:00+00:00\",\"dateModified\":\"2025-01-27T10:08:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23422\"},\"wordCount\":205,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"COVID-19\",\"Panlong Pharmaceutical\",\"Patents\",\"SHE: 002864\",\"TPD\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23422#respond\"]}],\"copyrightYear\":\"2022\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23422\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=23422\",\"name\":\"Shaanxi Panlong Receives Patents for Coronavirus 3CL Protease Inhibitor - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2022-12-22T10:03:00+00:00\",\"dateModified\":\"2025-01-27T10:08:22+00:00\",\"description\":\"China-based Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864) has announced receiving two patents (US11518759B1, US11530195B1) in relation to a development project titled \\\"Coronavirus 3CL Protease Inhibitor Development,\\\" in collaboration with Shaanxi University of Science and Technology. The patents cover \\\"PROTACs [proteolysis-targeting chimeric molecules] based on VHL ligand targeting coronavirus 3CL protease, preparation method and application thereof.\\\"\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23422#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=23422\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=23422#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shaanxi Panlong Receives Patents for Coronavirus 3CL Protease Inhibitor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shaanxi Panlong Receives Patents for Coronavirus 3CL Protease Inhibitor - Insight, China's Pharmaceutical Industry","description":"China-based Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864) has announced receiving two patents (US11518759B1, US11530195B1) in relation to a development project titled \"Coronavirus 3CL Protease Inhibitor Development,\" in collaboration with Shaanxi University of Science and Technology. The patents cover \"PROTACs [proteolysis-targeting chimeric molecules] based on VHL ligand targeting coronavirus 3CL protease, preparation method and application thereof.\"","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=23422","og_locale":"en_US","og_type":"article","og_title":"Shaanxi Panlong Receives Patents for Coronavirus 3CL Protease Inhibitor","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=23422","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2022-12-22T10:03:00+00:00","article_modified_time":"2025-01-27T10:08:22+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=23422#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=23422"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shaanxi Panlong Receives Patents for Coronavirus 3CL Protease Inhibitor","datePublished":"2022-12-22T10:03:00+00:00","dateModified":"2025-01-27T10:08:22+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=23422"},"wordCount":205,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["COVID-19","Panlong Pharmaceutical","Patents","SHE: 002864","TPD"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=23422#respond"]}],"copyrightYear":"2022","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=23422","url":"https:\/\/flcube.com\/?p=23422","name":"Shaanxi Panlong Receives Patents for Coronavirus 3CL Protease Inhibitor - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2022-12-22T10:03:00+00:00","dateModified":"2025-01-27T10:08:22+00:00","description":"China-based Shaanxi Panlong Pharmaceutical Group Co., Ltd (SHE: 002864) has announced receiving two patents (US11518759B1, US11530195B1) in relation to a development project titled \"Coronavirus 3CL Protease Inhibitor Development,\" in collaboration with Shaanxi University of Science and Technology. The patents cover \"PROTACs [proteolysis-targeting chimeric molecules] based on VHL ligand targeting coronavirus 3CL protease, preparation method and application thereof.\"","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=23422#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=23422"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=23422#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shaanxi Panlong Receives Patents for Coronavirus 3CL Protease Inhibitor"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23422","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23422"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23422\/revisions"}],"predecessor-version":[{"id":23423,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/23422\/revisions\/23423"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23422"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23422"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23422"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}